LeMaitre Vascular Inc (LMAT) Expected to Announce Quarterly Sales of $26.29 Million

Equities research analysts expect LeMaitre Vascular Inc (NASDAQ:LMAT) to announce sales of $26.29 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for LeMaitre Vascular’s earnings. The lowest sales estimate is $26.00 million and the highest is $26.57 million. LeMaitre Vascular reported sales of $23.29 million in the same quarter last year, which would suggest a positive year over year growth rate of 12.9%. The company is expected to announce its next quarterly earnings report on Tuesday, February 20th.

On average, analysts expect that LeMaitre Vascular will report full-year sales of $26.29 million for the current fiscal year, with estimates ranging from $100.70 million to $101.28 million. For the next fiscal year, analysts expect that the business will report sales of $110.85 million per share, with estimates ranging from $109.90 million to $111.80 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.05. The business had revenue of $24.80 million during the quarter, compared to analyst estimates of $25.49 million. LeMaitre Vascular had a return on equity of 16.16% and a net margin of 15.81%. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.17 EPS.

LMAT has been the subject of several recent analyst reports. Zacks Investment Research raised LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a report on Thursday, December 28th. Canaccord Genuity reissued a “hold” rating and set a $30.00 price objective on shares of LeMaitre Vascular in a report on Monday, October 9th. BidaskClub lowered LeMaitre Vascular from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 27th. First Analysis lowered LeMaitre Vascular from an “overweight” rating to an “equal weight” rating and set a $34.00 price objective for the company. in a report on Friday, October 27th. Finally, Benchmark lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, October 27th. One analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $32.20.

Shares of LeMaitre Vascular (NASDAQ LMAT) traded up $0.68 during midday trading on Friday, hitting $32.64. The stock had a trading volume of 107,788 shares, compared to its average volume of 109,071. LeMaitre Vascular has a 52 week low of $19.82 and a 52 week high of $39.88. The stock has a market capitalization of $628.81, a price-to-earnings ratio of 42.39, a price-to-earnings-growth ratio of 2.51 and a beta of 0.54.

In other news, insider David B. Roberts sold 4,123 shares of the business’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $32.14, for a total transaction of $132,513.22. Following the completion of the transaction, the insider now owns 24,482 shares of the company’s stock, valued at $786,851.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 23.70% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Thomson Horstmann & Bryant Inc. lifted its position in LeMaitre Vascular by 10.6% in the 4th quarter. Thomson Horstmann & Bryant Inc. now owns 356,517 shares of the medical instruments supplier’s stock worth $11,351,000 after buying an additional 34,162 shares during the last quarter. California Public Employees Retirement System lifted its position in LeMaitre Vascular by 5.5% in the 3rd quarter. California Public Employees Retirement System now owns 52,283 shares of the medical instruments supplier’s stock worth $1,956,000 after buying an additional 2,736 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in LeMaitre Vascular in the 3rd quarter worth approximately $235,000. Janus Henderson Group PLC lifted its position in LeMaitre Vascular by 30.5% in the 3rd quarter. Janus Henderson Group PLC now owns 194,891 shares of the medical instruments supplier’s stock worth $7,293,000 after buying an additional 45,586 shares during the last quarter. Finally, Allianz Asset Management GmbH lifted its position in LeMaitre Vascular by 4.7% in the 3rd quarter. Allianz Asset Management GmbH now owns 321,820 shares of the medical instruments supplier’s stock worth $12,042,000 after buying an additional 14,306 shares during the last quarter. Institutional investors own 69.24% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://sportsperspectives.com/2018/01/14/lemaitre-vascular-inc-lmat-expected-to-announce-quarterly-sales-of-26-29-million.html.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply